What's the Difference Between NAFLD and MASLD?

The Rename Explained: NAFLD Out, MASLD In

In 2023, a global Delphi consensus of more than 230 hepatologists replaced "nonalcoholic fatty liver disease" with "metabolic dysfunction-associated steatotic liver disease." The new terminology is not cosmetic. It signals that fatty liver is a metabolic organ disease, not simply the absence of alcohol.

The old "nonalcoholic" label defined the condition by exclusion: you had NAFLD if you had liver fat and you did not drink heavily. That framing stigmatized patients and ignored the underlying metabolic drivers. MASLD flips the logic. To meet MASLD criteria a patient must have hepatic steatosis plus at least one of five cardiometabolic conditions: overweight or obesity (BMI >25 kg/m²), type 2 diabetes or prediabetes, hypertension, dyslipidemia, or insulin resistance [1]. Patients with steatosis and no cardiometabolic feature at all fall into a separate, rarer category called cryptogenic steatotic liver disease.

The severe inflammatory subtype, formerly called NASH (nonalcoholic steatohepatitis), is now MASH (metabolic dysfunction-associated steatohepatitis). Fibrosis staging, F0 through F4, did not change. Stage F3 (bridging fibrosis) and F4 (cirrhosis) remain the thresholds that most strongly predict liver-related mortality [2].

The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver jointly endorsed the new nomenclature, and most major journals adopted it through 2023 and 2024 [1]. Clinicians seeing records labeled NAFLD or NASH should treat them as synonymous with MASLD and MASH respectively.

Why the Distinction Matters for Patients

The rename has concrete downstream effects on clinical care, not just vocabulary.

Insurance coding. ICD-10 codes were updated to align with MASLD/MASH terminology, which affects prior-authorization language for emerging therapies. Patients applying for coverage of resmetirom, the first FDA-approved MASH drug, need documentation using the current diagnostic label.

Diagnostic precision. Requiring at least one cardiometabolic criterion means clinicians must actively document metabolic risk, not just rule out alcohol. A 2023 multi-cohort analysis estimated that roughly 38% of the global adult population meets MASLD criteria, compared with the older 25% NAFLD estimate, partly because metabolic documentation was historically incomplete [3].

Reduced stigma. A 2022 patient-preference survey (N=1,270) published in Hepatology found that 74% of patients preferred names that referenced the metabolic cause rather than a behavioral exclusion [4]. Language shapes engagement with care.

Research alignment. Trials funded after 2023 use MASLD/MASH endpoints, so reading older NASH literature requires translation. The histological endpoints are identical, NASH Activity Score, fibrosis staging, but endpoint names differ in trial registrations.

How Liver Fibrosis Is Measured Without a Biopsy

Liver biopsy remains the reference standard for fibrosis staging, but it carries a 1-in-1,000 serious complication rate and samples only 1/50,000th of the liver. Non-invasive tools are now preferred for initial assessment and monitoring [5].

Vibration-controlled transient elastography (FibroScan). This ultrasound-based device measures liver stiffness in kilopascals. A stiffness value <7.0 kPa effectively rules out significant fibrosis (F2 or above) with a negative predictive value above 90% in most MASLD cohorts [5]. Values above 12.0 kPa suggest advanced fibrosis or cirrhosis and should prompt specialist referral. FibroScan results can be influenced by BMI, ascites, and recent food intake, so the test is best performed after a 2-hour fast.

FIB-4 index. This blood-based score uses age, AST, ALT, and platelet count. A FIB-4 score <1.30 rules out advanced fibrosis in patients under 65 with a negative predictive value near 95% [6]. The 2023 AASLD MASLD guidance recommends FIB-4 as the first-line triage tool in primary care before any imaging is ordered [1].

MR elastography (MRE). More accurate than FibroScan, especially in patients with BMI >35 kg/m², MRE measures liver stiffness across the entire organ. Its main limitations are cost and scanner availability [7].

ELF panel. The Enhanced Liver Fibrosis blood panel (hyaluronic acid, PIIINP, TIMP-1) received FDA clearance for NASH fibrosis assessment in 2023. An ELF score >9.8 correlates with advanced fibrosis and raised all-cause mortality risk in a prospective cohort of 8,747 patients followed for a median of 6.8 years [8].

The practical pathway endorsed by AASLD: FIB-4 first. If FIB-4 is indeterminate (1.30 to 2.67), follow with FibroScan or ELF. Reserve biopsy for cases where non-invasive results conflict or where treatment eligibility requires histological confirmation [1].

Can MASLD Reverse with Diet Alone?

Yes, for patients without advanced fibrosis. Diet-induced weight loss of 7-10% body weight consistently reduces liver fat content, and 10% or more can resolve MASH histology entirely.

The PREDIMED-Plus substudy (N=294 patients with NAFLD/MASLD) demonstrated that an energy-restricted Mediterranean diet reduced liver fat by 29% relative to a control diet over 12 months, without a pharmacological intervention [9]. A meta-analysis of 21 randomized trials (N=1,530) published in Gastroenterology confirmed that patients achieving 10% weight loss had histological NASH resolution in 90% of cases and fibrosis improvement in 45% [10].

The Mediterranean dietary pattern consistently outperforms low-fat diets in MASLD trials. Its components with the strongest individual evidence include:

• Extra-virgin olive oil (substituted for saturated fats, at least 3 tablespoons daily in most trial protocols)
• Oily fish (2 servings per week; omega-3 EPA/DHA reduce hepatic triglyceride synthesis)
• Legumes and whole grains (lower glycemic load, reduce de novo lipogenesis)
• Reduced ultra-processed food and added-sugar intake (fructose drives hepatic fat synthesis through ChREBP activation)

Fructose deserves particular attention. Hepatic fructose metabolism bypasses the phosphofructokinase rate-limiting step of glycolysis, delivering substrate directly to de novo lipogenesis. Patients drinking two or more sugar-sweetened beverages daily have a 2.8-fold higher risk of MASLD than non-consumers in prospective cohort data [11].

Diet alone is usually insufficient once fibrosis reaches stage F2 or above. At that point, pharmacological or procedural intervention is needed alongside dietary change.

Does Coffee Actually Help Fatty Liver?

The evidence is stronger than most patients expect. Two or more cups of regular caffeinated coffee per day are associated with lower liver enzyme levels, lower liver fat content, and slower fibrosis progression across multiple observational cohorts.

A meta-analysis of 16 studies (N=3,153 patients with chronic liver disease) found that habitual coffee drinkers had a 39% lower risk of liver fibrosis progression and a 44% lower risk of cirrhosis compared with non-drinkers [12]. The proposed mechanisms include chlorogenic acid reducing lipid peroxidation, caffeine inhibiting hepatic stellate cell activation (the primary driver of fibrosis), and diterpenes modulating cytochrome P450 enzyme activity [13].

These are observational data. No randomized controlled trial has tested coffee as a formal MASLD therapy. However, no current guideline advises against moderate coffee consumption for MASLD patients who tolerate it, and the 2023 European MASLD clinical practice guidelines explicitly note a consistent inverse association between coffee intake and liver disease severity [14].

Decaffeinated coffee appears to share some benefits, suggesting that caffeine alone does not explain the effect. Green tea shows a similar signal in smaller cohorts, but the evidence base is thinner.

Are GLP-1 Receptor Agonists Effective for MASH?

GLP-1 receptor agonists are the most evidence-supported pharmacological class for MASH as of mid-2025, with semaglutide having the largest trial dataset.

The ESSENCE trial (N=800 patients with biopsy-confirmed MASH and F2 or F3 fibrosis) randomized patients to subcutaneous semaglutide 2.4 mg weekly or placebo. At 72 weeks, 62.9% of semaglutide patients achieved MASH resolution without fibrosis worsening, versus 34.1% on placebo (P<0.001) [15]. Fibrosis improvement by at least one stage occurred in 36.8% vs. 22.4% (P<0.001). The FDA accepted a supplemental NDA for semaglutide 2.4 mg in MASH in 2024, with a decision expected in 2025.

Liraglutide showed earlier proof-of-concept in the LEAN trial (N=52), where 39% of patients on liraglutide 1.8 mg daily achieved NASH resolution vs. 9% on placebo [16]. The smaller sample limits generalizability, but the mechanistic signal was consistent.

The mechanisms are multiple: GLP-1 agonists reduce hepatic fat through weight loss, and separately suppress hepatic de novo lipogenesis and inflammation through GLP-1 receptors expressed on hepatocytes and Kupffer cells. The anti-fibrotic effect seen in ESSENCE is not fully explained by weight loss alone and is an active research question.

Resmetirom (thyroid hormone receptor beta agonist, brand name Rezdiffra) received FDA approval in March 2024 for adults with MASH and moderate-to-advanced fibrosis (F2-F3), the first drug specifically approved for this indication [17]. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg achieved NASH resolution in 25.9% vs. 14.2% placebo and fibrosis improvement in 24.2% vs. 14.2% [17].

The HealthRX clinical team uses a tiered decision framework for MASH pharmacotherapy:

1. FIB-4 <1.30 with no diabetes: Structured lifestyle intervention first, 6-month reassessment.
2. FIB-4 1.30-2.67 or F1-F2 fibrosis with obesity or T2D: GLP-1 agonist as preferred first pharmacological agent, particularly if cardiometabolic co-treatment is also indicated.
3. Biopsy-confirmed MASH with F2-F3 and no dominant obesity/diabetes: Resmetirom monotherapy or combination considered.
4. F3-F4 fibrosis: Hepatology co-management required; liver transplant evaluation at F4 with decompensation.

Weight Loss Surgery and MASLD

For patients with BMI >35 kg/m² and MASH, bariatric surgery produces the most durable histological improvement of any current intervention.

A prospective cohort study (N=109 patients with biopsy-confirmed NASH before and 5 years after bariatric surgery) found complete NASH resolution in 85% of patients and fibrosis improvement in 34% at 5 years [18]. Roux-en-Y gastric bypass produced greater fibrosis regression than sleeve gastrectomy in an adjusted analysis, likely because of more pronounced improvements in insulin resistance and bile acid metabolism [18].

The 2022 ASMBS/IFSO guidelines list MASLD with fibrosis as a recognized indication for metabolic-bariatric surgery independent of BMI threshold, meaning patients with BMI 30-35 and significant fibrosis may qualify [19].

Alcohol Thresholds: Where MASLD Ends and ALD Begins

MASLD allows modest alcohol consumption within specific limits. The 2023 Delphi consensus defined the alcohol threshold as <20 g/day for women and <30 g/day for men (roughly 1.5 and 2 standard US drinks, respectively) [1]. Above those thresholds, the correct diagnosis shifts to MetALD (metabolic dysfunction-associated fatty liver with increased alcohol intake) or alcohol-associated liver disease, depending on consumption level.

This distinction matters for treatment. Alcohol reduction alone can produce significant steatosis regression, and GLP-1 agonists show promising signals for reducing alcohol intake in preclinical models and small human studies, though this is not yet an approved indication [20].

Patients near the threshold should be assessed using validated tools such as the AUDIT-C questionnaire. Clinicians should document alcohol intake in grams per day, not drinks, because standard drink size varies internationally.

Monitoring After Diagnosis

Once MASLD is diagnosed, monitoring frequency depends on fibrosis stage. AASLD guidance recommends:

• F0-F1: Annual FIB-4 and metabolic panel; FibroScan every 2 years if FIB-4 remains stable [1].
• F2-F3: FibroScan or MRE every 12 months; hepatology referral; hepatocellular carcinoma surveillance starts at F3 with cirrhosis features [1].
• F4 (cirrhosis): Abdominal ultrasound plus AFP every 6 months for HCC screening; upper endoscopy for varices screening at diagnosis [2].

Weight, waist circumference, HbA1c, fasting lipids, and liver enzymes should be tracked at each visit. ALT normalization is a reasonable short-term surrogate for steatosis reduction, though it does not reliably reflect fibrosis changes [6].

What Patients Often Miss: Visceral Fat Is the Target

Total body weight is a less precise target than visceral adipose tissue. Patients can have a "normal" BMI of 24.9 kg/m² and carry pathological amounts of intra-abdominal and intrahepatic fat. Conversely, metabolically healthy obesity (preserved insulin sensitivity, no dyslipidemia) carries a lower MASLD risk than the same BMI with metabolic dysfunction.

Waist circumference above 88 cm in women and 102 cm in men is a practical clinic proxy for excess visceral adipose tissue [3]. MRI-measured visceral fat volume correlates more tightly with intrahepatic triglyceride content than BMI does in metabolic phenotyping studies. For most patients, resistance training combined with aerobic exercise reduces visceral fat faster than aerobic exercise alone, even when total calorie expenditure is matched. A 12-week trial of combined training (N=220 adults with NAFLD) reduced intrahepatic lipid by 48% vs. 23% in the aerobic-only arm [21].

The 2023 EASL-EASD-EASO Clinical Practice Guidelines state: "Weight loss of at least 10% is the most effective lifestyle intervention to improve NASH histology, and structured exercise reduces liver fat independent of weight loss" [14].